IMTXImmatics N.V.
Price
+11%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 1% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for IMTX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities. Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.
In the company’s own words · 20-F filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.